New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
10:26 EDTANF, STI, TGT, VTR, WLH, CNQ, AVY, BIDU, LM, ATK, QLIK, MSFT, APAM, BBRY, BMY, CQP, INCY, IRWD, JNS, LRY, M, AYIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abercrombie & Fitch (ANF) upgraded to Buy from Neutral at Janney Capital... Artisan Partners (APAM) upgraded to Buy from Neutral at Goldman... BlackBerry (BBRY) upgraded to Sector Perform from Underperform at RBC Capital... Bristol-Myers (BMY) upgraded to Overweight from Equal Weight at Barclays... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Citigroup... Incyte (INCY) upgraded to Overweight from Equal Weight at Barclays... Ironwood (IRWD) upgraded to Outperform from Market Perform at BMO Capital... Janus Capital (JNS) upgraded to Neutral from Sell at Goldman... Liberty Property (LRY) upgraded to Buy from Neutral at UBS... Macy's (M) upgraded to Buy from Neutral at Goldman... Microsoft (MSFT) upgraded to Overweight from Equal Weight at Barclays... Qlik Technologies (QLIK) upgraded to Buy from Hold at Jefferies... SunTrust (STI) upgraded to Conviction Buy from Buy at Goldman... Target (TGT) upgraded to Buy from Neutral at Goldman... Ventas (VTR) upgraded to Buy from Neutral at UBS... William Lyon Homes (WLH) upgraded to Overweight from Neutral at JPMorgan... Canadian Natural (CNQ) upgraded to Outperform from Market Perform at BMO Capital... Avery Dennison (AVY) upgraded at Topeka... Baidu (BIDU) upgraded to Buy from Hold at Maxim... ATK (ATK) upgraded to Buy from Hold at Argus... Legg Mason (LM) upgraded to Neutral from Negative at Susquehanna... Acuity Brands (AYI) upgraded to Neutral from Underperform at Wedbush.
News For ANF;APAM;BBRY;BMY;CQP;INCY;IRWD;JNS;LRY;M;MSFT;QLIK;STI;TGT;VTR;WLH;CNQ;AVY;BIDU;LM;ATK;AYI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 14, 2014
06:46 EDTMSFTFirm indicates vulnerability in Microsoft Windows used by Russian hackers
Subscribe for More Information
06:32 EDTMSFTMicrosoft says hit 1M registrants to test Windows 10 preview version
Microsoft says on its Windows blog that it hit 1M registrants for the Windows Insider Program to test the preview version of Windows 10. The company says it has received 200,000 items of user feedback. Reference Link
06:02 EDTLMLegg Mason upgraded to Neutral from Underperform at BofA/Merrill
October 13, 2014
16:33 EDTMSFTMicrosoft and Salesforce.com unveil new joint solutions
Subscribe for More Information
16:04 EDTMSFTSkullcandy announces two ASTRO headsets compatible with Xbox One
Subscribe for More Information
13:10 EDTMSFTGoogle's Schmidt says Amazon is company's biggest search rival, FT reports
Eric Schmidt, the executive chairman of Google (GOOG), says Amazon (AMZN) is his company's biggest rival in search, not Bing (MSFT) or Yahoo (YHOO), the Financial Times reports. Schmidt also argued in Berlin that Google should not be regulated "as if it were the gatekeeper of the internet," given the influence of Amazon and Facebook (FB). Reference Link
10:06 EDTMJ.C. Penney rises after selecting Home Depot executive as next CEO
Subscribe for More Information
09:09 EDTMSFTMicrosoft Q1 results likely to beat expectations, says Bernstein
Bernstein believes that Microsoft's cloud business continues to grow, and it expects adoption of the company's cloud products to accelerate this quarter. The firm reiterates a $56 price target and Outperform rating on the shares.
08:34 EDTATKATK awarded $204M munitions contract by U.S. Army and allies
Subscribe for More Information
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
08:04 EDTJNSJanus to acquire VelocityShares, includes upfront cash consideration of $30M
Subscribe for More Information
07:46 EDTBBRYBlackBerry second half hardware estimates lowered at Canaccord
Canaccord lowered its second half of 2015 hardware estimates for Blackberry after surveys show limited availability of its new Passport smartphone. The firm, however, expects improving trends and believes Blackberry will achieve its target of reaching break-even cash low levels. Canaccord maintains its Hold rating and $10 price target on Blackberry shares.
07:15 EDTTGT, MSFTNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
06:15 EDTMJ.C. Penney downgraded to Sell from Neutral at UBS
UBS downgraded its rating on J.C. Penney (JCP) shares to Sell saying the company's 2017 EBITDA target of $1.2B is overly optimistic as it assumes years of market share gains against strong competitors like Macy's (M) and Kohl's (KSS). UBS halved its price target for Penney shares to $5 from $10. The retailer's stock closed Friday down 52c to $7.12.
October 10, 2014
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
10:01 EDTVTROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
08:00 EDTLMLegg Mason reports reports September prelim assets under management of $708B
Subscribe for More Information
06:16 EDTVTRVentas upgraded to Buy from Hold at Stifel
Stifel upgraded Ventas to Buy based on valuation. Price target is $70.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use